For many years, venture capitalists in biotech have depended on a well-established formula to generate profits through drug development. However, this reliable method is now being challenged by rapid changes in the industry, forcing investors to adapt to new trends and uncertainties.
Behind closed doors, health insurers and hospitals acknowledge that AI scribes are driving up healthcare expenses. However, they remain divided on how to address this growing financial challenge.
A small biotech company has been compelled to begin winding down its operations after the FDA unexpectedly postponed a critical meeting by four months. This delay has significant implications for the company's progress and highlights challenges within regulatory timelines. Meanwhile, Neurocrine Biosciences announced a new deal, signaling ongoing activity in the biotech sector despite setbacks faced by smaller players.
The FDA has given the green light to Eli Lilly's latest obesity medication, positioning it in direct rivalry with Novo Nordisk's recently launched Wegovy pill.
The Trump administration is reverting the federal health IT office's name to the Office of the National Coordinator, signaling a shift in its responsibilities and oversight.
Leading for-profit health insurance companies are experiencing a slowdown in job creation, with major insurers reducing their workforce. Additionally, upcoming Medicaid budget cuts threaten to compel hospitals to reduce staff numbers, signaling broader employment challenges in the healthcare sector.
Oni Blackstock argues that the integration of AI in healthcare should prioritize earning the trust of patients and providers over rapid financial investment. The development and deployment of AI technologies must move cautiously and transparently to avoid exacerbating the existing trust issues within medicine.
OB-GYNs are increasingly equipped and motivated to treat pain associated with gynecologic procedures, including IUD insertions, improving patient comfort and care quality.
AI agents designed to support health care tasks are becoming increasingly common, as showcased at HIMSS 2026. Despite their growing presence, experts emphasize the urgent need for rigorous validation to ensure these technologies are safe and effective before widespread adoption.
A health technology company specializing in remote patient monitoring is modifying its platform to participate in a new Medicare initiative. This program aims to better align healthcare payments with patient outcomes, focusing on chronic care management.
